Wilson J Liao

List of Publications by Year
in descending order

168 papers	11,150 citations	53794 45 h-index	33894 99 g-index
173 all docs	173 docs citations	173 times ranked	17073 citing authors

#	Article	IF	Citations
1	Influence of diet on the gut microbiome and implications for human health. Journal of Translational Medicine, 2017, 15, 73.	4.4	1,714
2	Genome-wide scan reveals association of psoriasis with IL-23 and NF-Î²B pathways. Nature Genetics, 2009, 41, 199-204.	21.4	1,229
3	A Genome-Wide Association Study of Psoriasis and Psoriatic Arthritis Identifies New Disease Loci. PLoS Genetics, 2008, 4, e1000041.	3.5	572
4	Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nature Genetics, 2009, 41, 211-215.	21.4	482
5	Regulatory T Cells in Skin Facilitate Epithelial Stem Cell Differentiation. Cell, 2017, 169, 1119-1129.e11.	28.9	477
6	Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17761-17766.	7.1	405
7	Influence of HLA-C Expression Level on HIV Control. Science, 2013, 340, 87-91.	12.6	352
8	Rare and Common Variants in CARD14, Encoding an Epidermal Regulator of NF-kappaB, in Psoriasis. American Journal of Human Genetics, 2012, 90, 796-808.	6.2	306
9	Memory regulatory T cells reside in human skin. Journal of Clinical Investigation, 2014, 124, 1027-1036.	8.2	294
10	Temporal Dissection of Tumorigenesis in Primary Cancers. Cancer Discovery, 2011, 1, 137-143.	9.4	240
11	Transcriptional Programming of Normal and Inflamed Human Epidermis at Single-Cell Resolution. Cell Reports, 2018, 25, 871-883.	6.4	206
12	Alteration of the cutaneous microbiome in psoriasis and potential role in Th17 polarization. Microbiome, 2018, 6, 154.	11.1	190
13	Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility. Nature Communications, 2015, 6, 6916.	12.8	154
14	A Subset of Methylated CpG Sites Differentiate Psoriatic from Normal Skin. Journal of Investigative Dermatology, 2012, 132, 583-592.	0.7	138
15	Machine Learning in Dermatology: Current Applications, Opportunities, and Limitations. Dermatology and Therapy, 2020, 10, 365-386.	3.0	132
16	Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation. JAMA Dermatology, 2018, 154, 934.	4.1	112
17	Tumor necrosis factor-Î± inhibitor-induced psoriasis: Systematic review of clinical features, histopathological findings, and management experience. Journal of the American Academy of Dermatology, 2017, 76, 334-341.	1.2	110
18	Genetic interplay betweenHLA-CandMIR148Ain HIV control and Crohn disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20705-20710.	7.1	109

#	Article	IF	Citations
19	Transcription Restores DNA Repair to Heterochromatin, Determining Regional Mutation Rates in Cancer Genomes. Cell Reports, 2014, 9, 1228-1234.	6.4	104
20	Sequencing of TNFAIP3 and association of variants with multiple autoimmune diseases. Genes and Immunity, 2011, 12, 176-182.	4.1	99
21	Phototherapy in Psoriasis: A Review of Mechanisms of Action. Journal of Cutaneous Medicine and Surgery, 2013, 17, 6-12.	1.2	99
22	The Role of the Skin and Gut Microbiome in Psoriatic Disease. Current Dermatology Reports, 2017, 6, 94-103.	2.1	99
23	The role of IL-17 in vitiligo: A review. Autoimmunity Reviews, 2016, 15, 397-404.	5.8	92
24	Meta-Analysis Confirms the LCE3C_LCE3B Deletion as a Risk Factor for Psoriasis in Several Ethnic Groups and Finds Interaction with HLA-Cw6. Journal of Investigative Dermatology, 2011, 131, 1105-1109.	0.7	89
25	A Genetic Risk Score Combining Ten Psoriasis Risk Loci Improves Disease Prediction. PLoS ONE, 2011, 6, e19454.	2.5	84
26	Diet and psoriasis, part I: Impact of weight loss interventions. Journal of the American Academy of Dermatology, 2014, 71, 133-140.	1.2	84
27	Diet and psoriasis, part II: Celiac disease and role of a gluten-free diet. Journal of the American Academy of Dermatology, 2014, 71, 350-358.	1.2	80
28	Landscape of Long Noncoding RNAs in Psoriatic and Healthy Skin. Journal of Investigative Dermatology, 2016, 136, 603-609.	0.7	80
29	Atopic dermatitis: Role of the skin barrier, environment, microbiome, and therapeutic agents. Journal of Dermatological Science, 2021, 102, 142-157.	1.9	80
30	Single-cell RNA sequencing of psoriatic skin identifies pathogenic Tc17 cell subsets and reveals distinctions between CD8+ T cells in autoimmunity and cancer. Journal of Allergy and Clinical Immunology, 2021, 147, 2370-2380.	2.9	77
31	The gut microbiome in psoriasis and psoriatic arthritis. Best Practice and Research in Clinical Rheumatology, 2019, 33, 101494.	3.3	75
32	Immunopathogenesis of hidradenitis suppurativa and response to antiâ€“TNF-Î± therapy. JCI Insight, 2020, 5, .	5.0	75
33	Genetic Epidemiology of Psoriasis. Current Dermatology Reports, 2014, 3, 61-78.	2.1	74
34	Network analysis of psoriasis reveals biological pathways and roles for coding and long non-coding RNAs. BMC Genomics, 2016, 17, 841.	2.8	74
35	Diet and psoriasis, part III: Role of nutritional supplements. Journal of the American Academy of Dermatology, 2014, 71, 561-569.	1.2	71
36	Further Genetic Evidence for Three Psoriasis-Risk Genes: ADAM33, CDKAL1, and PTPN22. Journal of Investigative Dermatology, 2009, 129, 629-634.	0.7	67

#	Article	IF	Citations
37	Psoriasis Patients Are Enriched for Genetic Variants That Protect against HIV-1 Disease. PLoS Genetics, 2012, 8, e1002514.	3.5	66
38	Frequency and Management of Sleep Disturbance in Adults with Atopic Dermatitis: A Systematic Review. Dermatology and Therapy, 2017, 7, 349-364.	3.0	66
39	Carriers of Rare Missense Variants in IFIH1 Are Protected from Psoriasis. Journal of Investigative Dermatology, 2010, 130, 2768-2772.	0.7	65
40	Dietary Behaviors in Psoriasis: Patient-Reported Outcomes from a U.S. National Survey. Dermatology and Therapy, 2017, 7, 227-242.	3.0	65
41	Association of Cardiovascular and Metabolic Disease Genes with Psoriasis. Journal of Investigative Dermatology, 2013, 133, 836-839.	0.7	62
42	Anti IL-17 in psoriasis. Expert Review of Clinical Immunology, 2019, 15, 1185-1194.	3.0	61
43	Dupilumab Treatment for Generalized Prurigo Nodularis. JAMA Dermatology, 2019, 155, 118.	4.1	60
44	Regulatory T cells use arginase 2 to enhance their metabolic fitness in tissues. JCI Insight, 2019, 4, .	5.0	60
45	A review of dupilumab in the treatment of atopic diseases. Human Vaccines and Immunotherapeutics, 2019, 15, 2129-2139.	3.3	53
46	Erythrodermic psoriasis: pathophysiology and current treatment perspectives. Psoriasis: Targets and Therapy, 2016, Volume 6, 93-104.	2.2	52
47	Tonsillectomy as a treatment for psoriasis: A review. Journal of Dermatological Treatment, 2014, 25, 482-486.	2.2	47
48	Risk of tuberculosis reactivation during interleukinâ€17 inhibitor therapy for psoriasis: a systematic review. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1449-1456.	2.4	42
49	The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review. Dermatology and Therapy, 2017, 7, 425-446.	3.0	40
50	Biologic Treatments of Psoriasis: An Update for the Clinician. Biologics: Targets and Therapy, 2021, Volume 15, 39-51.	3.2	40
51	Response to Interleukin (IL)-17 Inhibition in an Adolescent With Severe Manifestations of IL-36 Receptor Antagonist Deficiency (DITRA). JAMA Dermatology, 2017, 153, 106.	4.1	39
52	Skewed distribution of natural killer cells in psoriasis skin lesions. Experimental Dermatology, 2013, 22, 64-66.	2.9	38
53	The TNFRSF members CD27 and OX40 coordinately limit T _H 17 differentiation in regulatory T cells. Science Immunology, 2018, 3, .	11.9	38
54	The impact of genital psoriasis on quality of life: a systematic review. Psoriasis: Targets and Therapy, 2018, Volume 8, 41-47.	2.2	38

#	Article	IF	Citations
55	Which Psoriasis Patients Develop Psoriatic Arthritis?. Psoriasis Forum, 2010, 16a, 17-25.	0.1	37
56	Skin-infiltrating, interleukin-22â€“producing T cells differentiate pediatric psoriasis from adult psoriasis. Journal of the American Academy of Dermatology, 2017, 77, 417-424.	1.2	37
57	Ocular Co-Morbidities of Atopic Dermatitis. Part I: Associated Ocular Diseases. American Journal of Clinical Dermatology, 2019, 20, 797-805.	6.7	37
58	Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times. Dermatology and Therapy, 2020, 10, 339-349.	3.0	37
59	Dietary modifications in atopic dermatitis: patient-reported outcomes. Journal of Dermatological Treatment, 2017, 28, 523-538.	2.2	34
60	Acrodermatitis continua of Hallopeau: clinical perspectives . Psoriasis: Targets and Therapy, 2019, Volume 9, 65-72.	2.2	34
61	Antiviral gene expression in psoriasis. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1951-1957.	2.4	32
62	Inhibitory KIR3DL1 alleles are associated with psoriasis. British Journal of Dermatology, 2016, 174, 449-451.	1.5	32
63	Green technologies for room temperature nucleic acid storage. Current Issues in Molecular Biology, 2010, 12, 135-42.	2.4	32
64	Deletion of the activating <scp>NKG</scp>2C receptor and a functional polymorphism in its ligand <scp>HLA</scp>â€Ł in psoriasis susceptibility. Experimental Dermatology, 2013, 22, 679-681.	2.9	31
65	Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses. Journal of the American Academy of Dermatology, 2017, 77, 177-180.	1.2	31
66	RNA-seq and flow-cytometry of conventional, scalp, and palmoplantar psoriasis reveal shared and distinct molecular pathways. Scientific Reports, 2018, 8, 11368.	3.3	31
67	Meta-analysis of the TNFAIP3 region in psoriasis reveals a risk haplotype that is distinct from other autoimmune diseases. Genes and Immunity, 2015, 16, 120-126.	4.1	29
68	Treatment of Genital Psoriasis: A Systematic Review. Dermatology and Therapy, 2018, 8, 509-525.	3.0	29
69	How psoriasis patients perceive, obtain, and use biologic agents: Survey from an academic medical center. Journal of Dermatological Treatment, 2013, 24, 13-24.	2.2	28
70	Clinical and Genetic Risk Factors Associated with Psoriatic Arthritis among Patients with Psoriasis. Dermatology and Therapy, 2018, 8, 593-604.	3.0	28
71	The Patientâ€™s Guide to Psoriasis Treatment. Part 1: UVB Phototherapy. Dermatology and Therapy, 2016, 6, 307-313.	3.0	27
72	The metabolomics of psoriatic disease. Psoriasis: Targets and Therapy, 2017, Volume 7, 1-15.	2.2	27

#	Article	IF	Citations
73	Review of the mechanism of action of coal tar in psoriasis. Journal of Dermatological Treatment, 2018, 29, 230-232.	2.2	27
74	Ethnicity affects the presenting severity of psoriasis. Journal of the American Academy of Dermatology, 2017, 77, 180-182.	1.2	24
75	The Role of IL-17 Cytokines in Psoriasis. ImmunoTargets and Therapy, 2021, Volume 10, 409-418.	5.8	24
76	Scalp Psoriasis: A Literature Review of Effective Therapies and Updated Recommendations for Practical Management. Dermatology and Therapy, 2021, 11, 769-797.	3.0	23
77	How Long Does the Benefit of Biologics Last? An Update on Time to Relapse and Potential for Rebound of Biologic Agents for Psoriasis. Psoriasis Forum, 2010, 16a, 36-42.	0.1	22
78	Protective Effect of Human Endogenous Retrovirus K dUTPase Variants on Psoriasis Susceptibility. Journal of Investigative Dermatology, 2012, 132, 1833-1840.	0.7	22
79	Goeckerman therapy for the treatment of eczema: a practical guide and review of efficacy. Journal of Dermatological Treatment, 2013, 24, 2-6.	2.2	22
80	Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities. JAAD Case Reports, 2017, 3, 495-497.	0.8	21
81	New Frontiers in Psoriatic Disease Research,ÂPart II: Comorbidities and Targeted Therapies. Journal of Investigative Dermatology, 2021, 141, 2328-2337.	0.7	21
82	A pilot study demonstrating a nonâ€invasive method for the measurement of protein turnover in skin disorders: application to psoriasis. Clinical and Translational Medicine, 2013, 2, 12.	4.0	20
83	Ocular Co-Morbidities of Atopic Dermatitis. Part II: Ocular Disease Secondary to Treatments. American Journal of Clinical Dermatology, 2019, 20, 807-815.	6.7	20
84	Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis. JAAD Case Reports, 2019, 5, 928-930.	0.8	20
85	Factors Influencing Sleep Difficulty and Sleep Quantity in the Citizen Pscientist Psoriatic Cohort. Dermatology and Therapy, 2019, 9, 511-523.	3.0	20
86	New Frontiers in Psoriatic Disease Research, Part I: Genetics, Environmental Triggers, Immunology, Pathophysiology, and Precision Medicine. Journal of Investigative Dermatology, 2021, 141, 2112-2122.e3.	0.7	19
87	Which Psoriasis Patients Develop Psoriatic Arthritis?. Psoriasis Forum, 2010, 16, 17-25.	0.1	19
88	Biologic therapy in erythrodermic and pustular psoriasis. Journal of Drugs in Dermatology, 2014, 13, 342-54.	0.8	19
89	Genomic imprinting in psoriasis and atopic dermatitis: A review. Journal of Dermatological Science, 2015, 80, 89-93.	1.9	18
90	The Patientâ€™s Guide to Psoriasis Treatment. Part 2: PUVA Phototherapy. Dermatology and Therapy, 2016, 6, 315-324.	3.0	18

#	Article	IF	Citations
91	Transcriptional landscape of epithelial and immune cell populations revealed through FACS-seq of healthy human skin. Scientific Reports, 2017, 7, 1343.	3.3	18
92	The cumulative effects of known susceptibility variants to predict primary biliary cirrhosis risk. Genes and Immunity, 2015, 16, 193-198.	4.1	17
93	Emerging Methods to Objectively Assess Pruritus in Atopic Dermatitis. Dermatology and Therapy, 2019, 9, 407-420.	3.0	17
94	A Common Variant in CLDN14 is Associated with Primary Biliary Cirrhosis and Bone Mineral Density. Scientific Reports, 2016, 6, 19877.	3.3	16
95	‹p›Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives‹/p›. Psoriasis: Targets and Therapy, 2019, Volume 9, 97-107.	2.2	16
96	Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis . Journal of Inflammation Research, 2020, Volume 13, 53-60.	3.5	16
97	Scurvy: A presenting sign of psychosis. Journal of the American Academy of Dermatology, 2007, 57, S8-S10.	1.2	15
98	Increased expression of intrinsic antiviral genes in HLA-B*57-positive individuals. Journal of Leukocyte Biology, 2013, 94, 1051-1059.	3.3	15
99	Biologic Treatment of 4 HIV-Positive Patients: A Case Series and Literature Review. Journal of Psoriasis and Psoriatic Arthritis, 2021, 6, 19-26.	0.7	15
100	Dupilumab in patients with chronic hepatitis B on concomitant entecavir. JAAD Case Reports, 2019, 5, 624-626.	0.8	14
101	A review of current phase III clinical trials of plaque psoriasis: underâ€representation of nonwhite participants and need for reform. British Journal of Dermatology, 2021, 184, 348-350.	1.5	14
102	Secukinumab in the treatment of psoriasis: patient selection and perspectives. Psoriasis: Targets and Therapy, 2018, Volume 8, 75-82.	2.2	13
103	A cross-sectional study of psoriasis triggers among different ethno-racial groups. Journal of the American Academy of Dermatology, 2017, 77, 756-758.e1.	1.2	12
104	Novel Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis: Successful Recovery in Two Patients After Infection with Severe Acute Respiratory Syndrome CoronavirusÂ2 (SARS-CoV-2). Dermatology and Therapy, 2020, 10, 881-885.	3.0	12
105	Nail Psoriasis: A Review of Effective Therapies and Recommendations for Management. Dermatology and Therapy, 2021, 11, 799-831.	3.0	12
106	Insights from Î³-Secretase: Functional Genetics of Hidradenitis Suppurativa. Journal of Investigative Dermatology, 2021, 141, 1888-1896.	0.7	12
107	Hydroxyurea for the Treatment of Psoriasis with an Emphasis on HIV-Infected Psoriasis Patients: A Review. Psoriasis Forum, 2011, 17a, 180-187.	0.1	11
108	Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231986565.	2.5	11

#	Article	IF	Citations
109	Combined Single Cell Transcriptome and Surface Epitope Profiling Identifies Potential Biomarkers of Psoriatic Arthritis and Facilitates Diagnosis via Machine Learning. Frontiers in Immunology, 2022, 13, 835760.	4.8	11
110	The Patientâ€™s Guide to Psoriasis Treatment. Part 4: Goeckerman Therapy. Dermatology and Therapy, 2016, 6, 333-339.	3.0	10
111	Psoriasis risk SNPs and their association with HIV-1 control. Human Immunology, 2017, 78, 179-184.	2.4	10
112	Candidate long-range regulatory sites acting on the IL17 pathway genes TRAF3IP2 and IL17RA are associated with psoriasis. Experimental Dermatology, 2018, 27, 1294-1297.	2.9	10
113	Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN. Current Rheumatology Reports, 2020, 22, 78.	4.7	10
114	Genital and Inverse/Intertriginous Psoriasis: An Updated Review of Therapies and Recommendations for Practical Management. Dermatology and Therapy, 2021, 11, 833-844.	3.0	10
115	CD57 Expression and Cytokine Production by T Cells in Lesional and Unaffected Skin from Patients with Psoriasis. PLoS ONE, 2013, 8, e52144.	2.5	10
116	The Role of 39 Psoriasis Risk Variants on Age of Psoriasis Onset. ISRN Dermatology, 2013, 2013, 1-4.	1.9	9
117	Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date. Psoriasis: Targets and Therapy, 2018, Volume 8, 49-58.	2.2	9
118	How Long Does the Benefit of Biologics Last? An Update on Time To Relapse and Potential for Rebound of Biologic Agents for Psoriasis. Psoriasis Forum, 2010, 16, 36-42.	0.1	9
119	Multiomic Analysis of the Gut Microbiome in Psoriasis Reveals Distinct Hostâ€'Microbe Associations. JID Innovations, 2022, 2, 100115.	2.4	8
120	Transcriptomic Profiling of Plaque Psoriasis and Cutaneous T-Cell Subsets during Treatment with Secukinumab. JID Innovations, 2022, 2, 100094.	2.4	8
121	National Psoriasis Foundation Priorities for Patient-Centered Research: Proceedings from the 2016 Conference. Journal of Psoriasis and Psoriatic Arthritis, 2017, 2, 73-80.	0.7	7
122	Beyond the Booth. Dermatologic Clinics, 2020, 38, 157-163.	1.7	7
123	Nuclear Receptor Coactivator NCOA3 Regulates UV Radiationâ€"Induced DNA Damage and Melanoma Susceptibility. Cancer Research, 2021, 81, 2956-2969.	0.9	7
124	Large-Scale Imputation of KIR Copy Number and HLA Alleles in North American and European Psoriasis Case-Control Cohorts Reveals Association of Inhibitory KIR2DL2 With Psoriasis. Frontiers in Immunology, 2021, 12, 684326.	4.8	7
125	A Practical Approach to Home UVB Phototherapy for the Treatment of Generalized Psoriasis. Practical Dermatology, 2010, 7, 31-35.	0.0	7
126	TNF-Alpha Inhibitors and Ustekinumab for the Treatment of Psoriasis: Therapeutic Utility in the Era of IL-17 and IL-23 Inhibitors. Journal of Psoriasis and Psoriatic Arthritis, 2022, 7, 79-92.	0.7	7

#	Article	IF	Citations
127	Dietary Intervention and Supplements in the Management of Psoriasis: Current Perspectives. Psoriasis: Targets and Therapy, 0, Volume 12, 151-176.	2.2	7
128	The Patientâ€™s Guide to Psoriasis Treatment. Part 3: Biologic Injectables. Dermatology and Therapy, 2016, 6, 325-331.	3.0	6
129	Enteropathy in Psoriasis: A Systematic Review of Gastrointestinal Disease Epidemiology and Subclinical Inflammatory and Functional Gut Alterations. Current Dermatology Reports, 2018, 7, 59-74.	2.1	6
130	The Interaction of LILRB2 with HLA-B Is Associated with Psoriasis Susceptibility. Journal of Investigative Dermatology, 2020, 140, 1292-1295.e3.	0.7	6
131	Clinical Characteristics of 18 Patients with Psoriasis and Multiple Myeloma Identified Through Digital Health Crowdsourcing. Dermatology and Therapy, 2020, 10, 815-827.	3.0	6
132	Identifying Novel Psoriatic Disease Drug Targets Using a Genetics-Based Priority Index Pipeline. Journal of Psoriasis and Psoriatic Arthritis, 2021, 6, 185-197.	0.7	6
133	Hydroxyurea for the Treatment of Psoriasis including in HIV-infected Individuals: A Review. Psoriasis Forum, 2011, 17, 180-187.	0.1	6
134	Genome-Wide Association Study of Ustekinumab Response in Psoriasis. Frontiers in Immunology, 2021, 12, 815121.	4.8	6
135	Dupilumab for the treatment of severe photodermatitis. JAAD Case Reports, 2019, 5, 614-616.	0.8	5
136	Layilin Anchors Regulatory T Cells in Skin. Journal of Immunology, 2021, 207, 1763-1775.	0.8	5
137	Perspectives on the Future Development of Mobile Applications for Dermatology Clinical Research. Dermatology and Therapy, 2021, 11, 1451-1456.	3.0	5
138	Psoriasis and Cardiometabolic Comorbidities: An Evaluation of the Impact of Systemic Treatments in Randomized Clinical Trials. Dermatology and Therapy, 2021, 11, 1497-1520.	3.0	5
139	Bioinformatic applications in psoriasis: genetics, transcriptomics, and microbiomics. Seminars in Cutaneous Medicine and Surgery, 2019, 38, E3-E11.	1.6	5
140	No Evidence for Integrated Viral DNA in the Genome Sequence of Cutaneous Squamous Cell Carcinoma. Journal of Investigative Dermatology, 2014, 134, 2055-2057.	0.7	4
141	Tildrakizumab-asmn: Whatâ€™s in a Name?. American Journal of Clinical Dermatology, 2018, 19, 291-292.	6.7	4
142	A Rapid and Cost-Effective Device for Testing Minimal Erythema Dose. Dermatology and Therapy, 2018, 8, 483-489.	3.0	4
143	Building a Citizen Pscientist: Advancing Patient-Centered Psoriasis Research by Empowering Patients as Contributors and Analysts. Dermatology and Therapy, 2018, 8, 405-423.	3.0	4
144	Evaluation of a Genetic Risk Score for Diagnosis of Psoriatic Arthritis. Journal of Psoriasis and Psoriatic Arthritis, 2020, 5, 61-67.	0.7	4

#	Article	IF	Citations
145	Sleep and the Gut Microbiome in Psoriasis: Clinical Implications for Disease Progression and the Development of Cardiometabolic Comorbidities. Journal of Psoriasis and Psoriatic Arthritis, 2021, 6, 27-37.	0.7	4
146	Efficacy and safety of tildrakizumab 100Âmg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e526-e528.	2.4	4
147	Psoriasis and Exercise: A Review. Psoriasis: Targets and Therapy, 0, Volume 12, 189-197.	2.2	4
148	Tumor Necrosis Factor-Î± Triad: Psoriasis, Cardiovascular Disease, and Depression. Psoriasis Forum, 2013, 19a, 41-49.	0.1	3
149	A Pilot Study to Assess the Reliability of Digital Image-Based PASI Scores Across Patient Skin Tones and Provider Training Levels. Dermatology and Therapy, 2022, 12, 1685-1695.	3.0	3
150	How Long Does the Benefit of Biologics Last? An Update on Time to Relapse and Potential for Rebound of Biologic Agents for Psoriasis. Journal of Psoriasis and Psoriatic Arthritis, 2018, 3, 65-70.	0.7	2
151	Dupilumab-Induced Facial Flushing After Alcohol Consumption. , 2021, 108, 106-107.		2
152	Psoriasis Vulgaris Successfully Treated with Goeckerman Treatment at Home: A Patient and Physicianâ€™s Experience. Dermatology and Therapy, 2020, 10, 329-338.	3.0	1
153	Update on Sleep and Pulmonary Comorbidities in Psoriasis. Current Dermatology Reports, 2020, 9, 30-35.	2.1	1
154	Advancements in Biologic Therapy for Psoriasis: the IL-23 Inhibitors. Current Dermatology Reports, 2021, 10, 6-15.	2.1	1
155	Immunosuppressants, immunomodulators and COVID-19 vaccines: anticipating patient concerns. Journal of Dermatological Treatment, 2021, , 1-4.	2.2	1
156	Inpatient Management of Psoriasis: A Current Perspective and Update for Clinicians. Current Dermatology Reports, 2021, 10, 205-221.	2.1	1
157	The cumulative effects of known susceptibility variants to predict primary biliary cirrhosis risk. , 0, .		1
158	Efficacy and Safety of Tildrakizumab 100 Mg for Plaque Psoriasis in Patients Randomized to Treatment Continuation vs Treatment Withdrawal with Retreatment upon Relapse in Resurface 1. SKIN the Journal of Cutaneous Medicine, 2020, 4, s40.	0.3	1
159	A cross-sectional study of ethnoracial representation in pediatric plaque psoriasis clinical trials. Journal of the American Academy of Dermatology, 2022, 86, 442-444.	1.2	1
160	Demographic and Clinical Factors Associated with Patient-Reported Remission in Psoriasis. Dermatology and Therapy, 2022, 12, 753-760.	3.0	1
161	Biologics. Updates in Clinical Dermatology, 2018, , 73-92.	0.1	0
162	Examination of Tar-Induced Verrucous Growths Reveals Absence of Human Papillomavirus. American Journal of Dermatopathology, 2019, 41, 865-867.	0.6	0

#	Article	IF	Citations
163	Implementation of an Ultraviolet Phototherapy Service at a National Referral Hospital in Western Kenya: Reflections on Challenges and Lessons Learned. Dermatology and Therapy, 2020, 10, 107-117.	3.0	0
164	The future of personalized medicine in psoriasis. Dermatological Reviews, 2021, 2, 282.	0.5	0
165	Validation of Patient-Reported Psoriasis Diagnosis from a Global Online Research Network. Journal of Investigative Dermatology, 2021, 141, 2539-2541.	0.7	0
166	Biologics update: ILâ€23 inhibitors. Dermatological Reviews, 2021, 2, 276.	0.5	0
167	Defining Psoriasis Remission Based on Histopathologic and Molecular Criteria: A Systematic Literature Review. Journal of Investigative Dermatology, 2022, 142, 2026-2029.e4.	0.7	0
168	The psoriasis glycome: differential expression of cholesterol particle glycans and IgA glycans linked to disease severity. Journal of Investigative Dermatology, 2022, , .	0.7	0